Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Avanir Pharmaceuticals, Inc.
NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Avanir Pharmaceuticals ("Avanir" or the "Company") (NasdaqGS: AVNR). The investigation focuses on whether the Company and its executives violated federal securities laws.
On September 11, 2013, shares of Avanir fell around 13% or $0.74 to close at $4.79 after Gravity Research posted a report on the website Seeking Alpha, alleging the following potential issues: illegal off-label marketing of Nuedexta, a perceived likelihood of losing a patent case over the drug, and possible financial difficulties. Shares of the Company closed on September 13, 2013 to trade at $4.08
If you are aware of any facts relating to this investigation, or purchased shares of Avanir, you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC